Celldex Therapeutics, Inc. Royalty Expense
Celldex Therapeutics, Inc. (CLDX) reported Royalty Expense of $2.33 million for the 12-month period ending 2013-12-31, per its 10-K/A filed 2016-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2016-02-25
- Celldex Therapeutics, Inc. royalty expense for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- Celldex Therapeutics, Inc. royalty expense for the quarter ending 2013-09-30 was $0.00, a 100.00% decline year-over-year.
- Celldex Therapeutics, Inc. royalty expense for the quarter ending 2013-06-30 was $0.00, a 100.00% decline year-over-year.
- Celldex Therapeutics, Inc. royalty expense for the quarter ending 2013-03-31 was $2.33M, a 0.43% decline year-over-year.
- Celldex Therapeutics, Inc. royalty expense for fiscal 2013 was $2.33M, a 78.34% decline from fiscal 2012.
- Celldex Therapeutics, Inc. royalty expense for fiscal 2012 was $10.78M, a 18.16% increase from fiscal 2011.
- Celldex Therapeutics, Inc. royalty expense for fiscal 2011 was $9.12M, a 24.49% decline from fiscal 2010.
- Celldex Therapeutics, Inc. royalty expense for fiscal 2010 was $12.08M, a 43.83% increase from fiscal 2009.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-02-25 | $0.00 derived: sum of 2 quarters · filed 2016-02-25 | $0.00 derived: sum of 3 quarters · filed 2016-02-25 | $2.33M 10-K/A · filed 2016-02-25 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $0.00 derived: sum of 2 quarters · filed 2014-11-05 | $2.33M 10-Q · filed 2014-11-05 | $5.88M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $2.33M 10-Q · filed 2014-08-07 | $5.88M derived: sum of 3 quarters · filed 2015-02-24 | $8.89M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $2.33M 10-Q · filed 2014-05-01 | $5.88M derived: sum of 2 quarters · filed 2015-02-24 | $8.89M derived: sum of 3 quarters · filed 2015-02-24 | $10.76M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $6.56M derived: sum of 2 quarters · filed 2015-02-24 | $8.43M derived: sum of 3 quarters · filed 2015-02-24 | $10.78M 10-K · filed 2015-02-24 |
| 2012-09-30 | $3.01M 10-Q · filed 2013-11-08 | $4.88M derived: sum of 2 quarters · filed 2013-11-08 | $7.22M 10-Q · filed 2013-11-08 | $9.58M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | $1.87M 10-Q · filed 2013-08-06 | $4.22M 10-Q · filed 2013-08-06 | $6.58M derived: sum of 3 quarters · filed 2014-03-03 | $8.89M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | $2.34M 10-Q · filed 2013-05-03 | $4.70M derived: sum of 2 quarters · filed 2014-03-03 | $7.02M derived: sum of 3 quarters · filed 2014-03-03 | $8.96M derived: sum of 4 quarters · filed 2014-03-03 |
| 2011-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $4.68M derived: sum of 2 quarters · filed 2014-03-03 | $6.62M derived: sum of 3 quarters · filed 2014-03-03 | $9.12M 10-K · filed 2014-03-03 |
| 2011-09-30 | $2.32M 10-Q · filed 2012-11-02 | $4.26M derived: sum of 2 quarters · filed 2012-11-02 | $6.76M 10-Q · filed 2012-11-02 | $13.56M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-06-30 | $1.94M 10-Q · filed 2012-08-09 | $4.44M 10-Q · filed 2012-08-09 | $11.24M derived: sum of 3 quarters · filed 2013-03-08 | $12.46M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-03-31 | $2.50M 10-Q · filed 2012-05-04 | $9.30M derived: sum of 2 quarters · filed 2013-03-08 | $10.52M derived: sum of 3 quarters · filed 2013-03-08 | $12.25M derived: sum of 4 quarters · filed 2013-03-08 |
| 2010-12-31 | $6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $8.02M derived: sum of 2 quarters · filed 2013-03-08 | $9.75M derived: sum of 3 quarters · filed 2013-03-08 | $12.08M 10-K · filed 2013-03-08 |
| 2010-09-30 | $1.22M 10-Q · filed 2011-11-03 | $2.95M derived: sum of 2 quarters · filed 2011-11-03 | $5.28M 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $1.73M 10-Q · filed 2011-08-04 | $4.06M 10-Q · filed 2011-08-04 | ||
| 2009-12-31 | $8.40M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |